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Background: Vertebroplasty is a minimally invasive procedure demonstrated to be safe 
and effective in the treatment of painful osteoporotic and malignancy related fractures when 
performed in the thoracolumbar spine. Multiple randomized and nonrandomized reports have 
demonstrated its effectiveness. Conversely, transoral vertebroplasty (TOV) to treat the second 
cervical vertebra (C2) has been described in only a few case reports. 
Objectives: Prospective evaluation of clinical results of TOV performed in malignant painful 
osteolytic lesions of C2.
Study Design: TOV was performed in 25 consecutive patients suffering from high-grade 
cervical pain due to malignant involvement of C2 who failed conservative therapies and did not 
have surgical indications. Follow-up was prospectively evaluated with clinical interviews in all 
patients. The Internal Review Board approved this study.
Setting: Institute for Cancer Research and Treatment
Methods: Twenty-five patients (16 women and 9 men; mean age 59.3 ± 11.5) suffering from a 
painful malignant involvement of C2 who did not respond to conventional therapies and did not 
have surgical indications, underwent TOV for pain palliation. The procedure was performed under 
general anesthesia with combined digital fluoroscopy and computed tomography guidance. 
After a beveled vertebroplasty needle was manually advanced up to the posterior odontoid wall, 
bone cement was injected under continuous digital fluoroscopic control. Patients were discharged 
from the hospital the next procedural day. The Visual Analog Scale (VAS) for pain, analgesic 
requirement, and use of external cervical cast support were used for evaluating efficacy. The main 
end point was safety and efficacy at day 15 after the procedure. Furthermore, all the patients 
were scheduled to be followed-up at months one, 3, and 6, and every 6 months thereafter.
Results: The median pretreatment VAS of 8 (range 5-10) significantly  dropped (P < 0.0001) 
to 0 (range 0-10), with 20 patients (80%) achieving complete pain relief at day 15 after TOV. 
Differences in pre- and post-treatment analgesic therapy were significant (P < 0.001). Twenty-
three patients no longer used a cervical cast after TOV (92%, P < 0.001). At median overall 
follow-up of 16 months (range 6-60 months), the projected proportion of patients free from 
worsening pain at 6, 12, and 24 months was 96%, 96% and 92% respectively.
Limitations: A randomized study of only 25 patients.
Conclusion: TOV is safe, effective, and long-lasting in the treatment of cervical pain resulting 
from malignant involvement of C2.
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Methods 
Study design and patient population
This study was designed as a single cohort with 
consecutive prospectively acquired data. The data ex-
amined after transoral vertebroplasty were cement 
leakages, clinical complications, analgesic drugs re-
quirements, external cervical cast support, and early 
and long-term pain management in patients with a ma-
lignant osteolytic lesion of C2 that was poorly respon-
sive to conventional therapies.
From July 2003 to January 2010, 25 patients (16 
women and 9 men; mean age 59.3 ± 11.5 from 39 to 77 
years) were referred to our institution suffering from 
a painful malignant involvement of C2 with impend-
ing fracture. In all patients computed tomography (CT) 
scans with 2 dimensional reconstruction and magnetic 
resonance (MR) (Fig. 1) confirmed an osteolytic lesion 
at C2 and did not reveal any lesion or compression to 
the spinal cord. Patients’ demographics are summarized 
in Table 1. 
A multidisciplinary team consisting of medical on-
cology, radiation therapy, interventional radiology, and 
spine surgery evaluated all patients. Patients were re-
ferred due to persistent pain as well as an absence of 
bone consolidation having failed previous noninvasive 
therapies such as chemotherapy, bisphosphonates, ra-
diotherapy, and analgesic drugs. All patients had been 
judged ineligible for spinal surgery because of high sur-
gical risk and comorbidity. To treat pain and impending 
fracture, transoral vertebroplasty was offered to the 
patients.
Patients were fully informed of potential treat-
ment-related complications and provided signed in-
formed consent before each procedure. Vertebroplasty 
has been offered as a standard palliative treatment at 
our institution since 2002. Outcomes data were col-
lected in a prospectively maintained database and the 
Internal Review Board approved this study.
Procedure
After monitoring vital parameters (ECG, blood 
pressure, O2 saturation) the patients were placed in the 
supine position on the digital angiography table (Allura 
X-per CT, Philips, The Netherlands) of the intervention-
al radiology suite. The patients were all premedicated 
with IV antibiotics (one gm of vancomycin hydrochlo-
ride and 100 mg of gentamycin immediately before the 
procedure). General anesthesia (propofol 200 mg and 
The spine is the most common site of metastasis, with 50% to 80% of patients presenting with spinal lesions during the course of their disease 
(1-4). Due to a relatively large blood flow, the thoracic 
spine is a frequent site of metastasis. The cervical spine, 
by contrast, is less commonly involved, accounting 
for only 8%- 20% of all spinal metastases (1,2,5-8). In 
particular, metastases to the cervical junction (C1 and 
C2) are uncommon and represent less than 1% of all 
spinal metastases (1,3).
Nonsurgical options for spinal metastases depend 
on tumor histology, the presence of neurologic symp-
toms, and spinal stability (1,9). Recent progress in an-
ticancer therapy (6,10) and newer radiotherapy tech-
niques such as cyberknife radiosurgery (6,10-12) or 
intensity modulated stereotactic radiotherapy (13,14) 
have improved the management of patients with spinal 
metastases. Unfortunately, a significant proportion of 
patients with spinal metastases will develop symptoms 
of bone progression during the course of the disease 
despite these therapies (15). In particular, patients with 
cervical metastases, because of the difficult anatomi-
cal localization, represent a subgroup where there are 
unmet medical needs. An osteolytic lesion at C2 with 
clinical signs of mechanical instability and uncontrolled 
pain is, in most cases, suggestive of an impending frac-
ture with high risk of severe consequences; in these pa-
tients, surgery (16-18) is a preferred option. However, 
surgical stabilization poses the risk of severe complica-
tions (17) since these patients present frequently with 
poor clinical conditions and an advanced, multi-meta-
static disease.
A less invasive procedure is represented by percuta-
neous vertebroplasty (PV), a technique first introduced 
by Galibert and Deramond in 1987 for the treatment 
of symptomatic vertebral angioma of C2 (19). Presently, 
PV is extensively applied for the palliative treatment 
of spine metastases in the thoracic and lumbar region 
(20-23). Despite being less invasive than surgery, cervi-
cal spine PV remains a challenging procedure. Only one 
relatively large series of PV for cervical metastases (24) 
and case reports of PV for malignant lesions of C2 have 
been reported in the medical literature (5,25-29).
In the current paper, we present a series of 25 pa-
tients who received minimally invasive transoral PV of 
C2 for painful malignant involvement, prospectively 
evaluated during long-term follow-up of 21.8 ± 16.3 
months (range 6-60 months).
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Fig. 1. (left to right) Magnetic resonance and computed tomography with 2 dimensional reconstruction pre-procedural evalua-
tion confirmed osteolytic lesion at C2 and did not reveal any lesion or compression to the spinal cord. Procedural CT confirmed 
needle placement within the lesion allowing satisfactory bone cement injection (lower left to right).
fentanyl 0.1 mg) was administered with placement of 
a flexible reinforced endotracheal tube. The oral cav-
ity and posterior oropharynx were then cleansed with 
povidone-iodine; a self-retaining pharyngeal retractor 
(an otolaryngologic device commonly used for tonsil 
resection) was then placed for tongue depression and 
visualization.
The caudocranial fluoroscopic projection allowed 
good visualization of the C2 odontoid process. Either 
a 15-gauge (4 patients) or 13-gauge (21 patients) 
beveled vertebroplasty needle (OptiMed, Ettlingen, 
Germany) were employed for the procedure. The 
posterior oropharynx wall was puncture under direct 
fluoroscopic guidance in the caudocranial projection. 
After a thru-cut bone biopsy was obtained coaxially 
using the Bard Magnum(Bard Inc., Tempe, AZ) for 
subsequent histopathological analysis, the vertebro-
plasty needle was manually advanced up to the pos-
terior odontoid wall during lateral fluoroscopic view. 
Prior to polymethylmethacrylate (PMMA) injection, 
rotational acquisition with 2 dimensional multipla-
nar reconstructions (2DMPR) was obtained in 21 pa-
tients to confirm correct needle position within the 
lesion. PMMA was then injected under continuous 
digital fluoroscopic control for early detection of 
possible PMMA leakages up to satisfactory bone le-
sion filling. The injection was performed with a low-
pressure gun, the Cemento-RE, (OptiMed, Ettlingen, 
Germany) for a better-graduated control of the in-
jection. After the stylet was reinserted, the needle 
was manually withdrawn. The patients were then 
awakened from anesthesia and underwent extuba-
tion. Patients were discharged from the hospital the 
next procedural day. A post-procedural 7-day course 
of oral clindamycin 150 mg every 6 hours was pre-
scribed for all patients.
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Assessment of Complications and Cement 
Leakage
Postprocedural 2DMPR were obtained in all the pa-
tients to precisely visualize the filling of the defect by 
the bone cement and to detect possible complications. 
Follow-up and Clinical Outcome Evaluation
A dedicated software database was developed to 
prospectively collect clinical data and technical infor-
mation on treated patients. 
Follow-up was completed by clinical interviews at 
2 and 15 days after vertebroplasty, and by clinical or 
phone interview thereafter (months one, 3, 6, 12, 18, 
and every 6 months).
Pain was evaluated by the 11-point pain intensity 
numerical rating Visual Analog Scale (VAS) where 0 rep-
resents no pain and 10 the worst experienced pain. The 
raw change in the VAS was computed by subtracting 
the baseline value from the endpoint for each patient. 
Analgesic drugs prescribed at baseline and at follow-up 
interviews were classified as none, nonsteroidal anti-
inflammatory drugs (NSAIDs), oral narcotic, and trans-
dermal or intravenous opioid therapy with implanted 
pump.
Statistical analysis
The outcome of interest was the change, with re-
spect to pretreatment values, of the following variables 
Table 1. Patients demographics before Vertebroplasty (VP) and at the end-point
Pt Sex Age Pathology
Brace 
before 
VP
Brace 
after 
VP
Analgesic
 before VP
Analgesic 
after VP
VAS 
before 
VP
VAS 
after 
VP
Follow-up 
(months)
SA F 69 HCC Mts Halo vest None I.V. opiates None 9 0 13
MG M 59 Thyroid Ca Mts Halo vest Minerva I.V. opiates NSAD 9 2 6
BL F 39 Breast Ca Mts Minerva None Oral opiates None 7 0 62
RL F 73 Gastric Ca Mts Minerva None Oral opiates NSAD 5 0 9
VI M 77 Renal Ca Mts Minerva None Oral opiates NSAD 10 3 60
MV F 59 Uterine Ca Mts Minerva None Oral opiates NSAD 8 3 25
AM F 52 Breast Ca Mts Minerva None Oral opiates None 6 0 45
EM M 43 Oropharyngeal Mts Minerva None Oral opiates None 7 0 9
PG M 60 Myeloma Halo vest None I.V. opiates NSAD 10 3 38
MA F 48 Breast Ca Mts Minerva None Oral opiates None 8 0 20
LB F 55 Breast Ca Mts Minerva None Transdermic opiates None 5 0 31
MR F 77 Hystiocytosis X Mts Halo vest None I.V. opiates NSAD 10 3 14
DP M 45 Nasopharyngeal Ca Mts Minerva None Oral opiates None 6 0 13
VC M 48 Myeloma Minerva None Oral opiates None 6 0 25
CFM F 52 Breast Ca Mts Minerva Minerva Transdermic opiates Oral opiates 10 10 24
VR F 66 Breast Ca Mts Minerva None Oral opiates None 5 0 23
FS M 47 Myeloma Minerva None Oral opiates None 9 0 16
LC F 47 Sarcoma Mts Minerva None Oral opiates NSAD 10 1 7
SE M 72 Colon Ca Mts Minerva None Oral opiates None 8 0 20
BR F 60 Breast Ca Mts Minerva None Oral opiates None 9 0 8
LL F 72 Myeloma Minerva None Oral opiates None 10 0 9
AAM F 56 Myeloma Minerva None Oral opiates None 10 0 14
PS F 66 Breast Ca Mts Minerva None Oral opiates None 8 0 6
DG M 76 Renal Ca Mts Minerva None Oral opiates None 10 0 6
CMS F 64 Breast Ca Mts Minerva None Oral opiates None 8 0 43
I.V.= Intravenous; NSAD= Non Steroidal Analgesic Drug; VAS= Visual Analog Scale
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measured at 15 days from the procedure: 
♦ The VAS, which was studied as both a continuous and 
a categorical ordinal variable
♦The pattern of analgesic use, which was coded into 
four categories: 1 = None, 2 = NSAIDs, 3 = oral opi-
ates, 4 = transdermal/intravenous opiates and stud-
ied as both a categorical nominal and categorical 
ordinal variable 
♦The use of an external orthopedic cast, which was di-
chotomized into “yes” or “no.”
Pain control failure occurring during follow-up was 
defined as a worsening of 2 or more VAS points with 
respect to the 15-day value. Time to pain relapse was 
studied by the Kaplan Meier method. Patients with-
out pain recurrence were amended at the date of the 
most recent follow-up contact. For the variables of in-
terest, pre- and post-PV values were compared by the 
Wilcoxon test (continuous variables), the McNemar test 
(dichotomous variables), and by the marginal homoge-
neity test (nominal variables with more than 2 levels). 
Significance was set at a P < 0.05.
Statistical analyses were performed by the SPSS 
Version 17 statistical package (SPSS Inc., Chicago, IL).
Results
Transoral vertebroplasty of C2 was feasible in all 25 
patients (Table 1 for demographics) without any early 
major complications such as death, symptomatic vascu-
lar leakages and spinal or extraspinal tissue injuries.
No delayed complications occurred during follow-
up. Specifically, no infections occurred in this group.
In 6 patients (24%), minimal PMMA leakage oc-
curred in the soft tissues surrounding the bone along 
the needle tract. All these leakages were asymptomatic 
and did not require any further treatment. One patient, 
with extensive osteolytic metastasis from thyroid can-
cer who obtained significant pain relief from PV, un-
derwent posterior surgical fixation after 6 months to 
increase bone consolidation.
Pain and Quality of Life Evaluation
Data regarding the variables of interest were avail-
able for the entire dataset of 25 patients.
All the patients had pretreatment VAS scores of 
5 or higher. All patients achieved a reduction in the 
VAS score of at least 2 points as a result of treatment 
(Table 2). The median VAS reduction was 7 points 
(range 2 to 10 points). The median pre- and post-
treatment VAS values were 8 (5-10) and 0 (0-10), re-
spectively, and the difference was statistically signifi-
cant by both the Wilcoxon test (considering VAS as a 
continuous variable, P < 0.001) and by the signed test 
(considering VAS as a categorical ordinal variable, P 
< 0.001). Notably, 24 patients (96%) achieved a clini-
cally relevant VAS reduction (2 or more points) with-
in 48 hours of the procedure. Twenty patients (80%) 
achieved complete pain relief (VAS = 0) within 15 
days after the procedure. At a minimum follow-up of 
6 months, (median 16 months, range 6 to 60 months), 
a total of 4 patients experienced worsening pain of 
2 or more VAS points (range 2-3 VAS points). The Ka-
plan Maier estimate of time to worsening pain is de-
picted in Fig. 2. The projected proportion of patients 
Table 2. Joined distribution of  VAS score before and after PV. The pre-treatment median VAS of  8 (range 5-10) significantly 
dropped to 0 (0-10) at the 15-day time point. 
VAS score after PV
VA
S 
sc
or
e 
be
fo
re
 P
V
0 1 2 3 4 5 6 7 8 9 10
0 - - - - - - - - - - -
1 - - - - - - - - - - -
2 -
3 -
4 -
5 3 -
6 3 -
7 2 -
8 4 1 -
9 3 1 -
10 3 1 3 1
Fig. 2. Kaplan Maier estimation of  time to worsening pain.
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Table 3. Analgesic drugs use before and after transoral vertebro-
plasty. Patient’s number and percentages before and after PV. 
Marginal homogeneity test: P <0.001
Sign test: P <0.001
Analgesic Medication
Before PV 
Number (%)
After PV
Number (%)
None 0 17 (68%)
NSAIDs 0 7 (28%)
Oral Opiates 21 (84%) 1 (4%)
Transdermic/I.V. opiates 4 (16%) 0 (0%)
(NSAIDs non-steroidal anti-inflammatory drugs; I.V., intra-
venous.)
free from worsening pain at 6, 12 and 24 months was 
96%, 96% and 92%, respectively.
Use of Analgesic Drugs
All the patients were on opiate analgesic drugs 
before the procedure, with 19 patients (76%) receiving 
oral opiates, 2 patients ( 8%) receiving transdermic opi-
ates, and 4 patients (16%) receiving intravenous opi-
ates (Table 1).
Table 3 summarizes the type and frequency of 
analgesic treatments before, and 15 days after the 
procedure. Differences in pre- and post-treatment fre-
quencies in each analgesic drug category were statis-
tically significant by the marginal homogeneity test 
(P < 0.001) and the sign test (P < 0.001). All but one 
patient achieved a downshift in the category of anal-
gesic drugs, with 17 patients (68%) discontinuing any 
analgesics use. 
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External Brace Support Evaluation
Before vertebroplasty, all the patients wore an or-
thopedic cervical cast (Halo vest in 4 and Minerva in 21). 
As a result of the procedure, 23 out of 25 of these pa-
tients (92%) no longer use it (Table 4 – P < 0.001).
Bone Cement Leakage
Post-procedural CT detected a minimal bone ce-
ment extravasation in 6 (24%) patients. Cross section-
al imaging with CT scans provides the most sensitive 
method of evaluating these leaks. These PMMA leak-
ages were located in the submucosal tissue along the 
needle track in 5 and into the left pedicular joint in 
one. All these leakages were asymptomatic during the 
procedure, post-procedural clinical observation, and at 
final follow-up.
discussion
Although PV is a widely performed procedure in 
vertebral osteoporotic compression fractures or for 
painful neoplastic vertebral involvement at the thoracic 
and lumbar level, this procedure is not well established 
as a treatment in the cervical spine (24) and is rarely 
performed in the upper C2 level (5,25-29). The antero-
lateral approach, commonly used for cervical percuta-
neous vertebroplasty, places many neurovascular struc-
tures at risk if performed to treat the second cervical 
vertebra: the spinal accessory, lingual, hypoglossal, va-
gus, marginal, and laryngeal nerves as well as carotid 
and vertebral arteries. For this reason a transoral ap-
proach is more frequently used in reported cases. 
Considering the high infection rate of cervicoverte-
bral spine surgery (17,30), minimally invasive transoral 
vertebroplasty has the potential advantage of lowering 
the infection rate for minimal disruption of the posterior 
oropharyngeal tissues. Surgical stabilization in cancer 
patients carries a risk of infection and the failure of bone 
healing due to poor clinical conditions and comorbidi-
ties (17,31). As a result, many patients do not undergo 
surgical treatment and are relegated to narcotics and 
chronic use of an external brace impacting quality of life 
and the ability to perform ADLs need full term for this 
abbreviation. The encouraging results of percutaneous 
vertebroplasty in the treatment of malignant vertebral 
body involvement and concomitant surgical high risk 
in these cancer patients led us to adopt this minimally 
invasive procedure. While not the established standard 
treatment, this is more appropriate for palliation and 
improvement of the quality of life of the patients with 
limited life expectancies and multi-metastatic disease.
As previously described in case reports, the advan-
tages of transoral vertebroplasty include precise needle 
placement, decreased risk to adjacent neurovascular 
structures, and potential reduction of infection rate. To 
minimize the complication rate and to obtain precise 
needle positioning, digital flat panel fluoroscopic guid-
ance with rotational CT imaging was always employed. 
We believe that this also increased the possibility of 
achieving an adequate cementation of C2.
In the majority of patients (20 out of 25 – 80%), 
pain relief was complete within 15 days from the pro-
cedure and this favorable clinical outcome was durable 
during an average follow-up of 16 months (from 6 to 60 
months) with 4 patients only showing worsening pain 
(VAS 2 to 3 points) during long-term evaluation. Con-
sidering quality of life, 92% of patients no longer re-
quired the external cervical brace after the procedure, 
and 17 out of 25 (68%) discontinued any analgesic use. 
These results are meaningful in cancer patients present-
ing with poor clinical conditions. 
Based on our experience, transoral vertebroplasty 
could be unsuccessful if the lesion extends to involve 
the posterior vertebral elements. In this situation, a 
satisfactory stabilization is difficult to achieve. In these 
select cases, by avoiding the risks of the anterior surgi-
cal approach, vertebroplasty and surgical posterior fixa-
tion may represent a safer option for patients present-
ing with this type of involvement as occurred in one 
patient of this series.
In this series treating osteolytic malignant C2 in-
volvement, we believe that minimal bone cement leak-
age occurred because of the use of high quality intra-
procedure image guidance employing digital flat-panel 
fluoroscopy and rotational CT. The observed leakages 
were limited (6 out of 25 – 24%) and asymptomatic 
both immediately after the procedure and during fol-
low-up, demonstrating that transoral vertebroplasty is 
a safe procedure.
Table 4. Joined distribution of  use of  brace before and after 
vertebroplasty. Numbers in rows contain represent pre-treatment 
frequencies and numbers in columns represent post-treatment 
frequencies. McNemar test: P <0.001
Halo/Minerva after PV
No Yes
Halo/Minerva 
before PV
No 0 0 0
Yes 23 2 25
23 2 25
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Study limitations include the relatively small num-
ber of patients as well as the lack of a control group 
treated by conservative medical therapy (radiotherapy 
and chemotherapy) only, but randomization was consid-
ered unethical when an impending fracture was present.
conclusion
Though surgery can achieve complete disease 
control if vertebrectomy and stabilization is per-
formed, there is a relatively high risk in cancer pa-
tients with poor clinical condition and advanced 
multi-metastatic disease. This relatively large nonran-
domized prospective series demonstrates that tran-
soral vertebroplasty is an effective and safe palliative 
treatment for painful malignant involvement of the 
second cervical vertebra in nonsurgical patients. In 
our opinion, this option should always be considered 
in this patient setting.
